Celera Corp. (NASDAQ:CRA), which was first to the finish line in the race to sequence the human genome, will be going out with a whimper barely a decade later when it is acquired by fellow diagnostic and pharmacogenetics company Quest Diagnostics Inc. (NYSE:DGX).

On paper, last week's deal price is $670.8 million in cash. But net of Celera's $327 million in cash, the transaction value is $344 million. This is less than 3% of the company